ScholarIQanswers from OpenAlex & ORCID
Kyriakos P. Papadopoulos
ResearcherPublications, citations & collaboration network
Kyriakos P. Papadopoulos is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kyriakos P. Papadopoulos have?
ScholarIQindexed works
Kyriakos P. Papadopoulos has 764 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kyriakos P. Papadopoulos have?
ScholarIQcitation count
Kyriakos P. Papadopoulos has 18,194 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kyriakos P. Papadopoulos?
ScholarIQh-index
Kyriakos P. Papadopoulos has an h-index of 64 in OpenAlex.
What is the i10-index of Kyriakos P. Papadopoulos?
ScholarIQi10-index
Kyriakos P. Papadopoulos has an i10-index of 206 in OpenAlex.
What is the ORCID of Kyriakos P. Papadopoulos?
ScholarIQorcid
The ORCID for Kyriakos P. Papadopoulos is on the source record.
What is the OpenAlex record for Kyriakos P. Papadopoulos?
ScholarIQopenalex
The OpenAlex for Kyriakos P. Papadopoulos is on the source record.
What are the most-cited papers on Kyriakos P. Papadopoulos?
ScholarIQmost cited works
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, John Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martínez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro
Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Anthony W. Tolcher, Wells A. Messersmith, Stanislaw M. Mikulski, Kyriakos P. Papadopoulos, Eunice L. Kwak, Darlene Gibbon, Amita Patnaik, Gerald S. Falchook, Arvind Dasari, Geoffrey I. Shapiro, John F. Boylan, Zhi-Xin Xu, Ka Wang, Astrid Koehler, James Song, Steven A. Middleton, Jonathan Deutsch, Mark DeMario, Razelle Kurzrock, Jennifer J. Wheler
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Glen J. Weiss, Jasgit C. Sachdev, Manpreet Chadha, Maddie Fulk, Samuel Ejadi, James M. Mountz, Michael T. Lotze, Frederico G. S. Toledo, Edward Chu, Michael Jeffers, Carol E. Peña, Chenjing Xia, Stefanie Reif, Isabelle Genvresse, Ramesh K. Ramanathan
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny Amore, Dirk Nagorsen, John S. Hill, Joe Stephenson
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer
Lars D. Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R. Smith, Svitlana Kulyk, J. David Lawson, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M. Briere, Alice Blaj, Matthew A. Marx, Jordi Rodón, Michael Offin, Kathryn C. Arbour, Melissa L. Johnson, David J. Kwiatkowski, Pasi A. Jänne, Candace L. Haddox, Kyriakos P. Papadopoulos, Jason T. Henry, Konstantinos Leventakos, James G. Christensen, Ronald Shazer, Peter Olson